Back to today’s briefing

Story perspectives

Viking Therapeutics Shares Plunge 43% After Disappointing Trial

8/20/2025

23 5

Summary

Story summary

Viking Therapeutics' shares declined by over 43% following unsatisfactory mid-stage trial results for VK2735, which resulted in an average 12.2% weight loss.
Around 28% of participants discontinued the trial due to gastrointestinal side effects, such as nausea and vomiting.
The company's market cap fell to approximately $2.8 billion, raising concerns about its competitiveness with Eli Lilly and Novo Nordisk.

1 of 1

Story summary

Viking Therapeutics' shares declined by over 43% following unsatisfactory mid-stage trial results for VK2735, which resulted in an average 12.2% weight loss.
Around 28% of participants discontinued the trial due to gastrointestinal side effects, such as nausea and vomiting.
The company's market cap fell to approximately $2.8 billion, raising concerns about its competitiveness with Eli Lilly and Novo Nordisk.